Global Healthcare Company Faces Drug Diversion Allegations

We represented a global healthcare company regarding a drug diversion allegation that controlled substances were inappropriately ordered, secured and dispensed by the company in violation of state and federal law. After conducting an internal investigation into the allegations and meeting with the DEA, the government declined to pursue further action against our client.

You Also May Be Interested In:

  • We successfully defended a national home healthcare provider in appealing an $18 million extrapolated overpayment resulting from a UPIC audit.

    We successfully defended a national home healthcare provider in appealing an $18 million extrapolated overpayment resulting from a UPIC audit....
    Client Type: Public Company
  • We represented a global for-profit health insurance company with more than 20 million members in False Claims Act (FCA) litigation in federal court in the Northern District of Illinois.

    We represented a global for-profit health insurance company with more than 20 million members in False Claims Act (FCA) litigation...
    Client Type: Private Company
  • Representation of ED company and other defendants in qui tam lawsuit alleging that ED provider’s violation of licensure laws caused submission of false claims and that defendants fraudulently billed services as performed by physicians even though patients were seen only by nurse practitioners. We obtained dismissal of the licensure claims and received summary judgment as to the upcoding claims. U.S. ex rel. Taylor v. Boyko, 2020 WL 520933 (S.D. W. Va. Jan. 31, 2020); U.S. ex rel. Taylor v. Perni, 2020 WL 2499544 (S.D. W. Va. May 14, 2020).

    We serve as lead counsel representing ED company and other defendants in qui tam lawsuit alleging that ED provider’s violation...